Literature DB >> 22798505

The mRNA expression of DAP1 in human breast cancer: correlation with clinicopathological parameters.

U Wazir1, W G Jiang, A K Sharma, K Mokbel.   

Abstract

UNLABELLED: This pilot study is the first to focus on the potential role of death-associated protein 1 (DAP1) in human breast cancer.
MATERIALS AND METHODS: A total of 153 samples were studied. DAP1 transcription levels were determined using quantitative polymerase chain reaction (qPCR). Transcript levels within breast cancer specimens were compared to those of normal background tissues and correlated with clinicopathological data accumulated over a 10-year follow-up period.
RESULTS: The expression of DAP1 mRNA was demonstrated to decrease with increasing Nottingham Prognostic Index (NPI2 vs. NPI3, p=0.0026), and TNM stage (TNM1 vs. 4, p=0.0039). Lower DAP1 expression levels were significantly associated with local recurrence (p=0.02) and distant metastasis (p=0.001).
CONCLUSION: This study demonstrates an inverse association between DAP1 mRNA levels and tumour stage and clinical outcome in breast cancer; thus, providing evidence that DAP1 plays a pro-apoptotic role in human breast cancer. The relationship between oncogenesis and the autophagy pathway merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798505

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  2 in total

1.  DAP1, a negative regulator of autophagy, controls SubAB-mediated apoptosis and autophagy.

Authors:  Kinnosuke Yahiro; Hiroyasu Tsutsuki; Kohei Ogura; Sayaka Nagasawa; Joel Moss; Masatoshi Noda
Journal:  Infect Immun       Date:  2014-09-02       Impact factor: 3.441

2.  Genome-wide association study of prevalent and persistent cervical high-risk human papillomavirus (HPV) infection.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo; Charles N Rotimi; Olayinka Olaniyan; Richard Offiong; Clement A Adebamowo
Journal:  BMC Med Genet       Date:  2020-11-23       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.